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Nosocomial infections with the Gram-positive path-
ogen Clostridium difficile pose a major risk for hospi-
talized patients and result in significant costs to
health care systems. Here, we present the chemical
synthesis of a PS-II hapten of a cell wall polysaccha-
ride of hypervirulent ribotype 027 of C. difficile. Mice
were immunized with a conjugate consisting of the
synthetic hexasaccharide and the diphtheria toxoid
variant CRM197. The immunogenicity of the glycan
repeating unit was demonstrated by the presence
of specific IgG antibodies in the serum of immunized
mice. Murinemonoclonal antibodies interact with the
synthetic hexasaccharide, as determined by micro-
array analysis. Finally, we found that specific IgA
antibodies in the stool of hospital patients infected
with C. difficile recognize the synthetic PS-II hexa-
saccharide hapten.
INTRODUCTION
TheGram-positive bacteria of the genusClostridiumdifficilehave
long been recognized as the cause of a range of gastrointestinal
diseases (HookmanandBarkin, 2009). Infection and thedevelop-
ment ofC. difficile-associated diseases (CDADs) are linked to the
use of antibiotics that disrupt the normal intestinal flora and allow
for proliferation of C. difficile (Thomas et al., 2003). C. difficile
infection in its most severe form can cause toxic megacolon
with subsequent colonic perforation, peritonitis, shock, and
death. Furthermore, C. difficile is a major cause of diarrhea in
hospital and long-term care facility patients due to the frequent
use of antibiotics, contamination of these facilities with resistant
spores, and because of the high density of susceptible persons.
A dramatic increase inC. difficile incidents was recorded inmany
developed countries (Polk et al., 2006) starting with reports of
hospital outbreaks in Canada in 2003 (Pe´pin et al., 2004). With
the increasing severity of the incidents, relapse and mortality580 Chemistry & Biology 18, 580–588, May 27, 2011 ª2011 Elsevierrates also increased significantly (Kuijper et al., 2007). The North
American and European outbreaks coincided with the emer-
gence of a hypervirulent strain of C. difficile, alternatively desig-
nated by the synonymous terms as PCR ribotype 027, toxin
type III, NAP1, and BI (McDonald et al., 2005; Loo et al., 2005).
Thehypervirulenceof ribotype027hasbeenascribed to its higher
toxin yields and an increased rate of sporulation (A˚kerlund et al.,
2008).Higher toxin content is due to anadditional toxin referred to
as thebinary toxinandageneticmutation in a toxin regulator gene
(tcdC), encoding a negative regulator of the C. difficile pathoge-
nicity locus. The isolates obtained during the North American
and European epidemics were genetically closely related and,
in addition, resistant to fluoroquinolones (Clements et al., 2010).
The medical significance of C. difficile has prompted intense
studies aiming to elucidate the structural composition of its cell
wall. Two capsular polysaccharides, PS-I and PS-II, were identi-
fied (Ganeshapillai et al., 2008). PS-I has a branched pentaglyco-
syl phosphate repeating unit, and PS-II a hexaglycosyl phos-
phate repeating unit. Both are found on the highly virulent
ribotype 027 (Figure 1). Currently, to our knowledge, no licensed
vaccine against C. difficile is available.
Several marketed vaccines are based either on natural poly-
saccharides alone (Lucas and Reason, 1999) or on polysaccha-
rides linked to immunogenic protein carriers (Hecht et al., 2009;
Roy, 2008). Polysaccharide-protein conjugate vaccines based
on isolated carbohydrates are an effective measure against at
least five different bacteria: Haemophilus influenzae type b,
Streptococcus pneumoniae, Neisseria meningitidis, Salmonella
typhi, and Staphylococcus aureus infections (Ada and Isaacs,
2003). A synthetic carbohydrate-protein conjugate vaccine
against Haemophilus influenzae type b was developed and mar-
keted in Cuba (Verez-Bencomo et al., 2004; Roy 2008).
Here, we report the synthesis of a hapten of the C. difficile
PS-II, its conjugation to the diphtheria toxoid CRM197, and the
production of monoclonal antibodies that specifically recognize
the glycan hapten. Polysaccharide-specific IgA antibodies were
detected in patients diagnosed with C. difficile infections. The
PS-II structure was selected as synthetic target because it was
reported to be found on severalC. difficile strains, including ribo-
type 027 (Ganeshapillai et al., 2008).Ltd All rights reserved
Figure 1. Retrosynthetic Analysis of Hexasaccharide Repeating Unit 2
(A) Structure of PS-II found on C. difficile.
(B) Retrosynthetic analysis of PS-II hapten analog 2.
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Oligosaccharide Repeating Unit Synthesis
The PS-II repeating units are interconnected via a (1/6) phos-
phate diester linkage in the natural polysaccharide (Figure 1).
We aimed to synthesize oligosaccharide 2 (Figure 1), which
constitutes a nonphosphorylated PS-II hexasaccharide hapten.
The oligosaccharide was designed to carry a primary amine at
the reducing terminus via a spacer to facilitate conjugation to
a protein carrier and attachment to microarrays. Based on our
retrosynthetic analysis, the hexasaccharide will be assembled
from themonosaccharide building blocks 3 and 4, and the disac-
charide building block 5 that appears twice in the target struc-
ture. Disaccharide 5will be derived in turn frommonosaccharide
building blocks 6 and 7. The building blocks 3, 4, 6, and 7 wereChemistry & Biology 18,synthesized from commercially available unprotected monosac-
charides following known methodology.
Preparation of the reducing terminus commenced with glyco-
sylation of the protected spacerN-benzyl-N-benzyloxycarbonyl-
5-aminopentanol 8 (Delcros et al., 2002) with mannose building
block 9 (Figures 1 and 2). The 2-O-benzoyl and 3-O-levulinoyl
protection groups on building block 9 were crucial for the
success of this glycosylation because when the alternative
mannose-based building block bearing 2-O-acetate and
3-O-fluorenylmethyloxycarbonyl (Fmoc) protecting groups was
used instead, it afforded mainly the orthoester product (Kong,
2007; Ravida` et al., 2006) and only small amounts of the desired
product. The levulinoyl ester inmannose glycoside 10was selec-
tively cleaved using hydrazine monohydrate to reveal the C3
hydroxyl group to give glycosyl acceptor 11.580–588, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 581
Figure 2. Synthesis of Building Blocks 11, 15, and 18
Reagents and conditions: (a) NIS, TMSOTf, CH2Cl2, 90%; (b) N2H4$H2O, AcOH, Py, quantitative; (c) TMSOTf, CH2Cl2, 30C, 78%; (d) Et3SiH, TfOH,
CH2Cl2,78C, 68%; (e) LevOH, DMAP, DIPC, CH2Cl2, 94%; (f) NIS, aqueous HCl, THF, 96%; (g) CF3C(NPh)Cl, Cs2CO3, CH2Cl2, 78%; (h) FmocCl, Py, CH2Cl2,
72%; (i) NBS, aqueous HCl, THF, 70%; (j) CF3C(NPh)Cl, Cs2CO3, CH2Cl2, quantitative. Lev, Levulinoyl; Bn, benzyl; Bz, benzoyl; Cbz, benzyloxycarbonyl; TCA,
trichloroacetyl.
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tosamine 6 (Chen et al., 2005) with the previously characterized
glucosyl phosphate 7 (Ravida` et al., 2006) via trimethylsilyl tri-
fluoromethanesulfonate-mediated activation of the anomeric
dibutyl phosphate leaving group in 7 followed by nucleophilic
substitution by 6 to afford disaccharide 12 (Figures 1 and 2).
The selective opening of the benzylidene acetal in compound
12, to afford disaccharide 13 bearing a 6-O-benzyl protection
group and no protection group on the C4 hydroxyl group,
strongly depended on the reaction conditions. Best results582 Chemistry & Biology 18, 580–588, May 27, 2011 ª2011 Elsevierwere obtained when disaccharide 12 was treated with triethylsi-
lane and triflic acid at78C. Other methods that relied on using
trimethylsilyl trifluoromethanesulfonate as Lewis acid, or sodium
cyanoborohydride as a reducing agent, furnished inseparable
mixtures of the 4-hydroxyl and 6-hydroxyl-regioisomers. The
free C4 hydroxyl group in disaccharide 13 was subsequently
masked as levulinoyl ester to afford glycosylating agent 5.
Hexasaccharide assembly commenced with the glycosylation
of monosaccharide 11 with phenyl selenide 5 to furnish trisac-
charide 19 with a yield of up to 61% (Depre´ et al., 1999). ToLtd All rights reserved
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by replacing the anomeric leaving group in 5. The phenyl sele-
nide in 5 was replaced by a different anomeric leaving group,
by a N-phenyl trifluoroacetimidate group (Yu and Tao, 2001).
Disaccharide 5 was converted, via lactol 14, to the correspond-
ing glycosyl N-phenyl trifluoroacetimidate 15. As envisioned,
glycosylation of nucleophile 11 with disaccharide N-phenyl tri-
fluoroacetimidate 15 yielded 82% of the desired product, which
compared favorably to the 61% obtained when phenyl selenide
5was used as disaccharide-glycosylating agent. The C2 partici-
pating trichloroacetamido group of galactosamine in 15 ensured
the exclusive formation of the b linkage. Treatment of trisaccha-
ride 19 with hydrazine monohydrate resulted in cleavage of the
levulinoyl ester and furnished 20 bearing a free hydroxyl group
ready for the next glycosylation. Glycosylation of trisaccharide
20 with thioglycoside 4 afforded a 55% yield of tetrasaccharide
21. The yield of this glycosylation was again improved when
N-phenyl trifluoroacetimidate glycoside 18 was employed
instead. This glycosylating agent in a mixture of methylene chlo-
ride and diethyl ether at 45C afforded 83% yield of tetrasac-
charide 21 containing the a-linked glucose. Glucose building
block 18 was prepared from known alcohol 16 (van Steijn
et al., 1992) via the procedure that was used for the conversion
of 5 to 15. Treatment of tetrasaccharide 21 with triethylamine
resulted in cleavage of the Fmoc group and liberation of the
hydroxyl group, ready for the next glycosylation. Hexasacchar-
ide 23 was obtained by the trimethylsilyl trifluoromethanesulfo-
nate-catalyzed glycosylation of tetrasaccharide 22 with disac-
charide building block 15.
Hexasaccharide 23 was freed from all protecting groups via
a three-step procedure. First, the N-trichloroacetyl groups
were transformed into N-acetyl groups by treatment with tributyl
stannane and azobisisobutyronitrile (AIBN) in toluene at 90C
(Figures 1 and 3) (Be´lot and Jacquinet, 2000; Rawat et al.,
2008). Subsequent saponification using potassium hydroxide
in tetrahydrofurane and methanol was followed by hydrogena-
tion using hydrogen gas and palladium on charcoal. Thereby,
hexasaccharide hapten 2 was obtained (Figures 1 and 3).
The anomeric region of the 13C and 1H-NMR spectra of hexa-
saccharide 2 are compared to that of the natural polysaccharide
(see Supplemental Experimental Procedures), confirming the
structure of hexasaccharide 2 despite slight differences. During
the preparation of this manuscript, an alternative synthesis of
a closely related hexasaccharide was published (Danieli et. al,
2011) where a similar comparison of NMR spectra of synthetic
hexasaccharide and natural polysaccharide was studied.
Preparation and Characterization
of Oligosaccharide-Protein Conjugate
Polysaccharide vaccines provoke a T cell-independent immune
response and do not induce an immunoglobulin class switch.
Therefore, polysaccharides are conjugated to immunogenic
carrier proteins that, unlike polysaccharides, induce a T cell-
dependent immune response. The synthetic hapten 2 of the
C. difficile glycopolymer PS-II was conjugated to the protein
carrier CRM197. The diphtheria toxoid CRM197 was chosen as
a carrier because it is a constituent of licensed vaccines
(Barocchi et al., 2007). A method based on the selective reaction
of the primary amine with squaric acid diester (Tietze et al., 1991)Chemistry & Biology 18,was selected from the multitude of methods for conjugation of
carbohydrates to proteins (Kuberan and Linhardt, 2000; Stall-
forth et. al, 2009). First, the amine group of the spacer moiety
in hexasaccharide 2 was reacted with one of the vinylogous
ester groups of 3,4-di-ethoxy-3-cyclobutene-1,2-dione in
pH 7.2 phosphate buffer to form the corresponding monoamine
24 that was purified by reverse-phase HPLC (Figure 4A). The
remaining ester group of monoamide 24 was subsequently
coupled with the 3-amino groups of lysine on the diphtheria
toxoid CRM197 in bicarbonate buffer at pH 9.0 to afford the
neoglycoconjugate. Successful conjugation was confirmed by
SDS-PAGE (Figure 4B), and the oligosaccharide/CRM197 ratio
was determined by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) (Figure 4C).
The mass analysis of CRM197 yielded a m/z ion at 58.6 kDa.
The mass spectrum of the neoglycoconjugate revealed mass
peaks between 59.9 and 67.3 kDa corresponding to mono- to
heptavalent glycoconjugates. On average four haptens 2 were
loaded on the diphtheria toxoid.
Immunization and Monoclonal Antibodies
To test the immunogenicity of the PS-II hapten, two female
C57BL/6 mice were immunized with the neoglycoconjugate.
Mice were injected three times subcutaneously (s.c.) with the
glycoconjugate at 2-week intervals. For each injection 15 mg
protein, as determined by Bradford analysis, was used. Consid-
ering an average loading ratio of four haptens on each protein,
the corresponding carbohydrate content was calculated as
being 1.3 mg. The anti-hapten 2 antibody titers were monitored
by glycan microarray analysis. Microarrays were designed for
high-throughput analysis, such that 64 samples could be
analyzed on one array with each well displaying hapten 2 and
seven control sugars in quadruplicates (Figure 5A). The two
immunized mice produced IgG antibodies that bound specifi-
cally to hapten 2 (Figure 5B), demonstrating that hapten 2 is
immunoreactive. An increase in the level of anti-hapten 2 specific
IgG antibodies over time was observed with mouse 2805.
To generate monoclonal antibodies, spleenocytes of the
immunized mice were fused to myeloma cells by the traditional
hybridoma technique (Ko¨hler and Milstein, 1975). The individual
hybridoma clones were screened to identify clones that produce
anti-hapten 2 antibodies. Three hybridoma clones that secrete
specific antibodies were obtained (Figure 5C). All three
hybridoma clones were derived from mouse 2805. Although
the monoclonal antibodies C2805.7 and C2805.21 bound exclu-
sively to hapten 2, antibody C2805.25 also interacted with
glucose on the array.
Specific IgA Antibodies in Infected Hospital Patients
Given the immunogenicity of the hexasaccharide hapten 2 in
mice, we wanted to know whether patients with CDAD produce
antibodies against the native glycopolymer. To this end, stool
supernatants of ten hospitalized patients with and without
C. difficile infection, as confirmed by the VIDAS immunoassay
(bioMe´rieux) that detects toxins A and B, were analyzed. Stool
supernatant rather than serum was chosen because the contact
site of the immune system with the cell surface glycopolymer is
the intestinal mucosa. Accordingly, IgA rather than IgG anti-
bodies are chiefly responsible for clearance of the pathogen580–588, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 583
Figure 3. Synthesis of Hexasaccharide 2
Reagents and conditions: (a) TMSOTf, CH2Cl2, 30C, 82%; (b) N2H4$H2O, Py, AcOH, CH2Cl2, 91%; (c) 18, TMSOTf, Et2O, CH2Cl2, 45C, 83%; (d) Et3N,
CH2Cl2, 85%; (e) 15, TMSOTf, CH2Cl2,30C, 63%; (f) 1. Bu3SnH, AIBN, toluene, 68%; 2. KOH, MeOH, THF, 86%; 3. H2, Pd/C, AcOH, THF, MeOH, H2O, 95%.
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epithelia against hexasaccharide 2, the glycan arrays described
above were incubated with the stool supernatants, and bound
IgA antibodies were visualized. Three persons had high titers
of anti-hexasaccharide 2 IgA antibodies in their stool (Figure 6).
Of these three patients, two had been diagnosed with C. difficile
toxin A/B-positive disease, whereas the third patient had
a borderline VIDAS test. Low amounts of anti-hexasaccharide
2 recognizing IgA antibodies were also detected in patients584 Chemistry & Biology 18, 580–588, May 27, 2011 ª2011 Elsevier2093, 2118, and 2121, which had not been diagnosed with
C. difficile toxin-positive disease. A possible explanation is colo-
nization with a nontoxigenic C. difficile strain or previous contact
with the bacterium.
DISCUSSION
Wereport anelegant synthesis ofC.difficilePS-II hexasaccharide
hapten that correlates with the structural assignment based onLtd All rights reserved
Figure 4. Conjugation and Analysis of the Hexasaccharide 2-CRM197 Glycoconjugate
(A) Hexasaccharide 2 was reacted with the carrier protein CRM197 via squaric acid route to yield a polyvalent neoglycoconjugate.
(B) SDS-PAGE analysis of the conjugation. Samples were electrophoresed on 12.5% SDS-PAGE gels and stained with Coomassie blue.
(C) MALDI-TOFMS analysis of the neoglycoconjugate. CRM197 with a m/z peak at 58.5 kDa; hexasaccharide 2-CRM197 conjugates with m/z peaks between 59.9
and 67.3 kDa.
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monosaccharide building blocks using an efficient and conver-
gent approach. A neoglycoconjugate comprising the hexasac-
charide hapten and the immunogenic carrier protein CRM197
was obtained. The outcome of the conjugation process was
monitored byMALDI-TOFMS and SDS-PAGE.Mice were immu-
nized with the neoglycoconjugate, and IgG antibody production
against hexasaccharide 2 was monitored by glycan microarray
analysis. The two animals produced antibodies specific for the
carbohydrate hapten, one of which showed a gradual increase
of the antibody’s affinity/concentration over the immunization
period.
High-throughput carbohydrate microarray analysis served as
a fast method to detect antibodies in murine sera, hybridoma
supernatant, and human excrement. Active ester conjugation
chemistry allowed for facile immobilization of the amine-termi-
nated synthetic hexasaccharide antigen to glass slides. In addi-
tion to hexasaccharide 2, seven control carbohydrates were
printed onto the microarray slides, and the entire array was
stable for more than 1 year. Carbohydrate microarray analysis
gave a detailed picture of the presence of antibodies, antibody
affinity and concentration, as well as cross-reactivity.
Using the microarrays, we detected specific anti-hexasac-
charide hapten 2 IgA antibodies in the stool supernatants ofChemistry & Biology 18,hospital patients. Two patients with significantly increased
C. difficile toxin A and B levels and one patient with a borderline
test displayed high amounts of highly specific anti-hexasacchar-
ide 2 IgA antibodies in their excrement. These observations
suggest that native glycopolymer PS-II exposes antigenic deter-
minants that are the targets of the immune response induced by
some patients infected with C. difficile. Antibodies in stool are
subject to different dilutions depending on the amount of daily
elimination; therefore, small variations in the concentrations of
the individual samples are likely. The three false-negative results
may be explained by the fact that these individuals were infected
with C. difficile strains that do not express PS-II. For the strains
prevalent in European hospitals (Zaiss et al., 2010), the expres-
sion of PS-II is only confirmed for ribotype 027. Because ribotyp-
ing is not performed routinely in European hospitals, the genetic
background of the pathogens responsible for the infections
analyzed in this study remains elusive. The low binding signal
recorded for three samples of patients without diagnosed
C. difficile infection can be accounted for by latent or previous
infections with bacteria of the clostridium type carrying PS-II.
In conclusion we show here that PS-II is an antigenic determi-
nant upon infections of humanswithC. difficile. Using a synthetic
fragment of PS-II as hapten, we further demonstrate immunoge-
nicity in mice and provide monoclonal antibodies specifically580–588, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 585
Figure 5. IgG in the Serum of Immunized Mice and Three Murine Monoclonal Antibodies Bind Hexasaccharide 2 on Glycan Microarrays
(A) Printing scheme of the glycan microarrays.
(B) IgG titers of immunized animals were analyzed before immunization (day 0), after the immunization (day 16), and after the first boost (day 30). Both mice
produced IgG antibodies to hexasaccharide 2. The microarray printing pattern is shown in the gray box.
(C) Monoclonal antibodies 2805.7, 2805.21, and 2805.25 raised against the neoglycoconjugate.
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analysis.SIGNIFICANCE
The synthesis of a hexasaccharide fragment of a C. difficile
cell surface polysaccharide gave access to chemically
defined and structurally homogeneous material equipped
with a primary amine handle. This handle allowed for conju-
gation of the synthetic oligosaccharide to the immunogenic
carrier protein CRM197 and to glass surfaces to produce
microarrays. The neoglycoconjugate was immunogenic in
mice and produced murine monoclonal antibodies that
specifically interact with the glycan hapten. The antibody-
binding specificities were determined by microarray anal-
ysis. Furthermore, microarrays were used to detect IgA anti-
bodies in the stool supernatant of infected hospital patients.
The presence of anti-hexasaccharide 2 IgA antibodies in
infected patients suggests a pivotal role of the PS-II in the586 Chemistry & Biology 18, 580–588, May 27, 2011 ª2011 Elsevierpathogenesis of C. difficile-associated diseases (CDADs).
Thus, both the natural polysaccharide and the synthetic
substructure are further studied as potential carbohydrate
conjugate vaccine candidates against C. difficile.
EXPERIMENTAL PROCEDURES
Chemical Synthesis
Detailed experimental procedures and characterization data for new
compounds are available online; see Supplemental Experimental Procedures.
Conjugation
Diethyl squarate (7.3 ml, 51 mmol) was added to a solution of hexasaccharide
C1 (2 mg, 1.7 mmol) in EtOH (0.2 ml) and phosphate buffer (0.2 ml, 50 mM
[pH 7.2]) and stirred for 18 hr at room temperature. Most ethanol was removed
by a stream of N2. Themixture was purified using a HPLC Superdex size exclu-
sion column (95:5 H2O/EtOH) to afford a colorless solid. A solution of the squa-
rate adduct (0.7 mg, 546 nmol) and the diphtheria toxoid CRM197 (Calbiochem;
0.7 mg, 11.1 nmol) in NaHCO3 buffer solution (0.4 ml, 0.1 M [pH 9]) was shaken
for 48 hr at room temperature. The resulting mixture was purified by ultrafiltra-
tion (30 K, Amicon; Millipore) with PBS. The protein concentration was deter-
mined by Bradford analysis (Bio-Rad).Ltd All rights reserved
Figure 6. IgA Analysis of Stool Supernatant of Hospitalized Persons
The presence of IgA antibodies specific for hexasaccharide 2 was analyzed in stool supernatants of ten hospital patients.
(A) Glycan microarray experiment. Stool supernatant of each patient was analyzed in three adjacent microarray wells.
(B) Quantification of the fluorescence signals detected in the glycan microarray experiment. High titers of anti-hexasaccharide 2 IgA antibodies were detected in
patients 2095 (positive), 2122 (borderline), and 2131 (positive). Low-intensity signals were also detected in patients 2093, 2118, and 2121 (all diagnosed negative).
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Hexasaccharide 2-CRM197 glycoconjugate and unconjugated CRM197 were
dissolved in Laemmli buffer (0.125 M Tris, 20% [v/v] glycerol, 4% [w/v] SDS,
5% [v/v] b-mercaptoethanol, bromophenol [pH 6.8]) and boiled for 5 min.
Samples were run in 12.5% polyacrylamide gel and stained with 0.025%
(w/v) Coomassie brilliant blue R-250 in an aqueous solution containing 40%
(v/v) methanol and 7% (v/v) acetic acid.
MALDI-TOF MS
Conjugation was confirmed by MALDI-TOF MS using an Ultraflex-II TOF/TOF
instrument (Bruker Daltonics, Bremen, Germany) equipped with a 200 Hz
solid-state Smart beam laser. The mass spectrometer was operated in the
positive linear mode. MS spectra were acquired over an m/z range of 4,000–
80,000, and data were analyzed using FlexAnalysis software provided with
the instrument. The samples were lyophilized from 25 mM NH4HCO3
(pH 7.8). Sinapinic acid was used as the matrix, and samples were spotted
using the dried droplet technique.
Immunizations
Two female C57BL/6 mice were immunized s.c. with 15 mg hexasaccharide
2-CRM197 conjugate in complete Freund’s adjuvants where 15 mg refers to
the protein content. The mice were boosted twice with 15 mg hexasaccharide
2-CRM197 conjugate in incomplete Freund’s adjuvants in 2-week intervals.
After each injection, blood was collected, and serum titers (IgG) were analyzed
using microarrays. Prior to being sacrificed, mice received additional 10 mg
hexasaccharide 2-CRM197 in PBS i.p. on 3 consecutive days.
Preparation of Clostridium Microarrays
Eight oligosaccharides bearing an amine linker were immobilized on NHS-
activated slides. Besides hexasaccharide 2, mannose, glucose, galactose,
fucose, acetylglucosamine, lactose, and a b-galactoside337 were printed in
0.5 mM concentration onto the slides. Each spot was printed in quadruplicate
using a piezoelectric spotting device (S11; Scienion, Berlin, Germany). SlidesChemistry & Biology 18,were incubated in a humid chamber to complete reaction for 24 hr and stored
in a desiccator until usage.
Microarray Binding Assays
A FlexWell 64 (Grace Bio-Labs, Bend, OR, USA) grid was applied to the slides.
The resulting 64 wells were used for 64 individual experiments. The slide was
blocked with 2.5% (w/v) BSA and 0.05% (v/v) Tween 20 in PBS for 1 hr at room
temperature. Blocked slides were washed with PBS and incubated with 5%
(v/v) serum in PBS or hybridoma culture supernatant for 1 hr at room temper-
ature. Slides were washed with PBS and incubated with 10 mg/ml Alexa Fluor
594 goat anti-mouse IgG and Alexa Flour 594 goat anti-mouse IgM (both
Invitrogen) secondary antibody solutions in PBS with 1% (w/v) BSA. Slides
were washed with PBS and centrifuged to dryness. Slides were scanned using
a GenePix 4300A scanner (Bucher Biotec, Basel, Switzerland) and evaluated
using the GenePix Pro 7 software (Bucher Biotec).
Monoclonal Antibody Purification
Supernatant of the hybridoma clones was filtered through a 0.2 mm filter. The
supernatant was mixed 1:1 with binding buffer (0.1 M NaP, 0.15 M NaCl
[pH 7.4]) and loaded onto a Midi Protein G spin column (Proteus, Oxford,
UK). The spin column was washed twice with binding buffer. Subsequently,
the IgG was eluted with elution buffer (0.2 M glycan/HCl [pH 2.5]) and immedi-
ately neutralized with 1 M Tris/HCl (pH 9). The eluted antibody solution was
purified by ultrafiltration (100 K, Amicon; Millipore) with PBS containing
0.01% (w/v) sodium azide. Protein-stabilizing cocktail (Pierce, Rockford, IL,
USA) was added to the concentrated antibody solution, and the protein
concentration was determined by Bradford analysis (Bio-Rad).
Analysis of Stool Supernatant
A FlexWell 64 (Grace Bio-Labs) grid was applied to the slides. The wells were
blocked with 2.5% (w/v) BSA and 0.05% (v/v) Tween 20 in PBS for 1 hr at room
temperature. Blocked slides were washed with PBS and incubated with 20 ml
stool supernatant of ten hospitalized persons (Charite´, Berlin) for 1 hr at room
temperature. Slides were washed with PBS and incubated with 10 mg/ml goat580–588, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 587
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A Possible Vaccine Candidate for C. difficileanti-human IgA FITC Conjugate (Invitrogen) secondary antibody solutions in
PBS with 1% (w/v) BSA. Slides were washed with PBS and centrifuged to
dryness. Slides were scanned using a GenePix 4300A scanner and evaluated
using the GenePix Pro 7 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
andcanbe foundwith this articleonlineat doi:10.1016/j.chembiol.2011.03.009.
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